The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired
securities of MannKind Corporation (“MannKind” or the “Company”)
(Nasdaq:MNKD) between August 10, 2015 and
January 5, 2016.
You are hereby notified that a securities class action lawsuit
has been commenced in the USDC for the Central District of California.
If you purchased or otherwise acquired MannKind securities between
August 10, 2015 and January 5, 2016, your rights may be affected by this
action. To get more information go to:
http://zlk.9nl.com/mannkind
or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com
or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There
is no cost or obligation to you.
The complaint alleges that throughout the Class Period Defendants issued
false and misleading statements and/or failed to disclose that: (1)
contrary to Defendants’ assurances, the mandated pulmonary testing or
spirometry was still a significant issue impeding sales of Afrezza, the
Company’s rapid-acting insulin; and (2) as a result, Defendants’
statements about MannKind’s business, operations, and prospects, were
false and misleading and/or lacked a reasonable basis at all relevant
times.
If you suffered a loss in MannKind you have until March
15, 2016 to request that the Court appoint you as lead
plaintiff. Your ability to share in any recovery doesn’t require that
you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New
Jersey, California, Connecticut and Washington D.C. The firm’s attorneys
have extensive expertise in prosecuting securities litigation involving
financial fraud, representing investors throughout the nation in
securities and shareholder lawsuits. Attorney advertising. Prior results
do not guarantee similar outcomes.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160302006429/en/
Copyright Business Wire 2016